3 transcripts
DMAC
Earnings call transcript
NASDAQ
2024 Q2
8 Aug 24
of a reduction in the cost of directors and officers liability insurance premiums, and decreased legal fees incurred in connection with our lawsuit against PRA
DMAC
Earnings call transcript
NASDAQ
2024 Q1
9 May 24
of the recent judgment in our lawsuit against PRA. We have secured capped and contingent fee arrangements with our councils to limit the potential cost
DMAC
Earnings call transcript
NASDAQ
2023 Q2
15 Aug 23
to support the ReMEDy2 trial and our lawsuit with PRA. Now we believe that our current capital will support the clinical development of DM199 and our
- Prev
- 1
- Next